Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|March 23, 2020
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)Inger Johanne Zwicky Eide, Åslaug Helland, Simon Ekman, et al.Journal of Medical Virology|October 10, 2013
Prevalence of human papillomaviruses in patients with head and neck squamous cell carcinoma in Lithuania and BelarusZivile Gudleviciene, Janina Didziapetriene, Irina Mackeviciene, et al.The Lancet. Oncology|May 25, 2010
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyFederico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, et al.Discover Oncology|December 18, 2024
Comparison of targeted next generation sequencing assays in non-small cell lung cancer patientsIeva Drejeriene, Jurate Gruode, Saulius Cicenas, et al.Translational Lung Cancer Research|July 14, 2022
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trialsInger Johanne Zwicky Eide, Simone Stensgaard, Åslaug Helland, et al.Lung Cancer (Amsterdam, Netherlands)|July 18, 2025
Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doubletAstrid Paulus, Marius Zemaitis, Saulius Cicenas, et al.Lung Cancer (Amsterdam, Netherlands)|February 22, 2026
Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study)Elin Marie Stensland, Simone Stensgaard, Inger Johanne Z Eide, et al.Acta Oncologica (Stockholm, Sweden)|September 6, 2021
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II studyInger Johanne Zwicky Eide, Harald Grut, Åslaug Helland, et al.Acta Oncologica (Stockholm, Sweden)|March 19, 2026
How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?Frigg Å Sommervoll, Henrik Horndalsveen, Dag Einar Sommervoll, et al.Frontiers in Oncology|November 7, 2025
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumabHenrik Horndalsveen, Vilde Drageset Haakensen, Tesfaye Madebo, et al.Pageof 5